Analytical characteristics of faecal and serum calprotectin or calprotectin assay: What clinical interest?

Raihane Bahri; Fadoua Elfarssani; Siham Khayati; Saida Eddyb; Hajar Saffour; Abderrahman Boukhira; Saliha Chellak

doi:10.30574/gscarr.2021.6.3.0052

Authors

Raihane Bahri Department of Biochemistry-Toxicology, Avicenne military hospital in Marrakech, Marrakech 40000, Morocco.
Fadoua Elfarssani Department of Biochemistry-Toxicology, Avicenne military hospital in Marrakech, Marrakech 40000, Morocco.
Siham Khayati Department of Biochemistry-Toxicology, Avicenne military hospital in Marrakech, Marrakech 40000, Morocco.
Saida Eddyb Department of Biochemistry-Toxicology, Avicenne military hospital in Marrakech, Marrakech 40000, Morocco.
Hajar Saffour Department of Biochemistry-Toxicology, Avicenne military hospital in Marrakech, Marrakech 40000, Morocco.
Abderrahman Boukhira Department of Biochemistry-Toxicology, Avicenne military hospital in Marrakech, Marrakech 40000, Morocco.
Saliha Chellak Faculty of medicine and pharmacy of Marrakesh, Morocco.

DOI:

https://doi.org/10.30574/gscarr.2021.6.3.0052

Keywords:

Calprotectin, IBD, rheumatoid arthritis, ELISA

Abstract

Calprotectin is a calcium binding protein expressed at the inflammatory site by neutrophils and monocytes to activate the innate immune system. Thanks to this unique characteristic, it is a good indicator of local inflammation in chronic inflammatory rheumatism.

All of the data highlight the key role that calprotectin plays in the inflammatory process in several inflammatory rheumatism. The value of serum and faecal calprotectin assays has been widely studied in recent years, in particular in rheumatoid arthritis, spondyloarthritis, juvenile idiopathic arthritis and vasculitis associated with ANCA but also for chronic inflammatory bowel disease. calprotectin has been identified as a powerful biomarker that allows the evaluation and monitoring of the activity of disease but also to predict structural evolution or response to treatment. Calprotectin is also a predictive biomarker of risk relapse. In this review, we discuss the value of calprotectin in chronic inflammatory affections as a diagnostic, potency or prognostic biomarker.

Metrics

Metrics Loading ...

References

Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen.Eur J Biochem. 1983; 134: 1-6.

Ridinger K, Ilg EC, Niggli FK, Heizmann CW, Schafer BW. Clustered organization of S100 genes in human and mouse. Biochim Biophys Acta. 1998; 1448: 254-63.

Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, NaessAndresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997; 50: 113-23.

Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C, Roth J. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J. Mol. Biol. 2006; 359: 961–97.

Clohessy PA, Golden BE. Calprotectinmediated zinc chelation as a biostatic mechanism in host defence. Scand. J. Immunol. 1995; 42: 551–556.

Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8 : myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003; 60: 569-80.

Voganatsi A, Panyutich A, Miyasaki KT, Murthy RK. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 2001; 70: 130-4.

Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990; 336: 763-5.

Loomans HJ, Hahn BL, Li QQ, Phadnis SH, Sohnle PG. Histidine-based zinc-binding sequences and the antimicrobial activity of calprotectin. J Infect Dis. 1998; 177: 812-4.

Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34: 50-4.

Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease : diagnostic meta-analysis. BMJ. 2010; 341: c3369.

Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol. 2011; 46: 694-700.

Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2013; 109: 637-45.

Yui S, Nakatani Y, Hunter MJ, Chazin WJ, Yamazaki M. Implication of extracellular zinc exclusion by recombinant human calprotectin (MRP8 and MRP14) from target cells in its apoptosis-inducing activity. Mediators Inflamm. 2002; 11: 165–172.

BÜHLMANN Laboratories AG ,Serum Calprotectin (MRP8/14; S100A8/S100A9) MF065ML-01E, Monitoring Rheumatoid Arthritis.

Clohessy PA, Golden BE. His-X-X-X-His motif in S100 protein, calprotectin: relation to microbiostatic activity. J. Leukoc. Biol. 1996; 60: 674.

Brodersen DE, Nyborg J, Kjeldgaard M. Zinc-binding site of an S100 protein revealed. Two crystal structures of Ca2+-bound human psoriasin (S100A7) in the Zn2+-loaded and Zn2+-free states. Biochemistry. 1999; 38: 1695–1704.

Moroz OV, Antson AA, Grist SJ, Maitland NJ, Dodson GG, Wilson KS et al. Structure of the human S100A12-copper complex: implications for host-parasite defence. Acta Crystallog. sect. D. 2003; 59: 859–867.

Harding MM. The architecture of metal coordination groups in proteins. Acta Crystallog. sect. D. 2004; 60: 849–859.

King DA, Zhang L, Guarente L, Marmorstein R. Structure of a HAP1-DNA complex reveals dramatically asymmetric DNA binding by a homodimeric protein. Nature Struct. Biol. 1999; 6: 64–7.

Asberg A, Lofblad L, Felic A, et al. Measuring calprotectin in plasma and blood with a fully automated turbidimetric assay. Scand J Clin Lab Invest. 2019; 79(1–2): 50–57.

Kalla R, Kennedy NA, Ventham NT, et al. Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases. Am J Gastroenterol. 2016; 111(12): 1796–1805.

Pepper RJ, Draibe JB, Caplin B, et al. Association of serum calprotectin (s100a8/a9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol Hoboken NJ. 2017; 69: 185–93.

Li SP, Goldman ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry. 1996; 35: 9060–8.

Andrés Cerezo L, Mann H, Pecha O, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011; 13: R122.

Levitova A, Hulejova H, Spiritovic M, Pavelka K, Senolt L, Husakova M. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res Ther. 2016;18:275.

Urban CF, Ermert D, Schmid M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 2009; 5: e1000639.

Bjarnason I, Helgason KO, Geirsson AJ, et al. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003; 125: 1598–605.